Receive regular headline summaries whenever high-quality news is generated for this page. We'll never share your email address with others.
|12/17/2020||Miach Orthopaedics‚Äô BEAR¬Æ Implant Granted FDA De Novo Approval for Treatment of ACL Tears
... digitally."As the use of our MolecuLight i: X platform is growing rapidly across multiple healthcare settings, so too is the need for EHR integration of our images and digital wound measurements," says Anil Amlani, MolecuLight's CEO. "We are proud to announce our strategic alliance with Net Health and Tissue ...
|12/17/2020||FDA accepts Takeda's NDA, grants review for budesonide oral suspension
... granted priority review fo r TAK-721, an investigational therapy budesonide oral suspension intended for the treatment of eosinophilic esophagitis. ‚ÄúEoE is a chronic, immune-mediated, inflammatory disease localized in the esophagus,‚Äù Karen Lasch, MD, vice president , g astroenterology, U.S. Medical , told Healio Gastroenterology . ‚ÄúIf left untreated, inflammation of ...
|5/9/2019||U.S. Food & Drug Administration Accepts Takeda’s Biologics License Application for a Subcutaneous Formulation of Vedolizumab (Entyvio®) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
... with none leading to treatment discontinuation. 1,2 “The VISIBLE 1 study provides us with important knowledge on the characterization of the efficacy and safety profile for the investigational subcutaneous formulation of vedolizumab,” said Karen Lasch, M.D., Medical Head, Specialty GI, U.S. Medical Office, Takeda. “Takeda is deeply committed to bringing ...
|11/9/2017||New Post-Hoc Analysis Evaluating Deep Remission with Entyvio® (vedolizumab) in Patients with Moderately to Severely Active Ulcerative Colitis Recognized as "Poster of Distinction" at AIBD 2017 Annual Conference||PR Newswire|
|11/9/2017||New Post-Hoc Analysis Evaluating Deep Remission with Entyvio® (vedolizumab) in Patients with||PR Newswire|
|10/16/2017||New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Patients Taking Entyvio® (vedolizumab), Particularly in Biologic-Naïve Patients||PR Newswire|
|10/16/2017||New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active||PR Newswire|